title: [Consumption of medications during the cholera epidemic in Douala, Cameroon (2004)].
abstract: To prepare for cholera outbreaks, stockpiles of supplies, rehydration salts/ solutions and appropriate antibiotics must be placed in strategic locations to ensure a prompt and effective response. However specific needs have not been evaluated up to now. The purpose of this report is to give an accurate account of medical supplies that were consumed during the cholera epidemic in Douala in 2004. Consumption of medication for the entire epidemic was measured by crosschecking data from the provincial pharmaceutical supply centre with the order forms, stock sheets and records of hospitals. Cost was calculated based on pricing data from the National Supply Center. For the 5 020 confirmed cases of cholera that were treated in the 14 hospitals in Douala from January to September 2004, consumption consisted of 499,746 doxycycline tablets, 235,881 amoxicilline tablets, 122,781 rehydration salt packets, and 60,217 units of Ringer Lactate (500 ml). The total cost of medications and consumables was 52,229,311 CFAF (approximately 80,000 Euro). Although updated recommendations are not available, comparison with the existing ones shows that the consumption levels observed were 5 times higher for both rehydration and antibiotherapy. The mean cost of treatment in Douala was 13 Euro per reported patient. This cost rose to 15 Euro if antibiotic prophylaxis was prescribed for all contacts. These findings can be useful in planning for future epidemics by allowing recommendations to be updated. We propose the follow supply levels for 50,000 inhabitants with an attack rate of 0.2%: 10,000 doxycycline tablets, 5000 amoxicilline tablets (500 mg), 2500 SRO packs (for 2500 liters) and 600 liters of Ringer Lactate.
authors.affiliation: Délégation Provinciale de la Santé publique du Littoral, Douala, Cameroon. guevart_edouard@yahoo.fr
authors.forename: E
authors.initials: E
authors.lastname: Guévart
authors.forename: J
authors.initials: J
authors.lastname: Sollé
authors.forename: J M
authors.initials: JM
authors.lastname: Bikoti
authors.forename: J
authors.initials: J
authors.lastname: Noeske
authors.forename: A
authors.initials: A
authors.lastname: Mouangue
mesh_terms: D000293:Adolescent; D000328:Adult; D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use; D002163:Cameroon / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D002771:Cholera / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D004196:Disease Outbreaks; D004318:Doxycycline / Q000191:economics / Q000627:therapeutic use; D004363:Drug Utilization / Q000706:statistics & numerical data*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007552:Isotonic Solutions / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015532:Rehydration Solutions / Q000191:economics / Q000627:therapeutic use; D000077325:Ringer's Lactate
chemical_list: D000900:Anti-Bacterial Agents; D007552:Isotonic Solutions; D015532:Rehydration Solutions; D000077325:Ringer's Lactate; D000658:Amoxicillin; D004318:Doxycycline